Compare Incyte Corporation (INCY) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Workiva Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Workiva Inc trades at $73.25 (market cap $4.01B). The key difference: Incyte Corporation is far larger — about 5.7× Workiva Inc's market cap, and Incyte Corporation is more actively traded (1,927,029 versus 1,301,708). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Workiva Inc for 21 Days on average.
| INCY | WK | |
|---|---|---|
Market Cap | $22.85B | $4.01B |
Volume | 1,927,029 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $129.93 | $93.31 |
52-Week Low | $83.80 | $44.31 |
Typical Hold Time | 33 Days | 21 Days |
Enterprise Value | $18.35B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Workiva (WK) trades at $73.69, up 3.02% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and AI product innovations at Amplify 2026 conference highlight operational strength. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and an $86 consensus price target.
WK presents a compelling growth story with improving profitability and strong analyst support, though elevated valuation multiples and technical overbought conditions warrant caution. The stock's 88.89% buy rating and 16.7% upside to consensus target suggest continued optimism, but investors should monitor execution of AI initiatives and competitive pressures in the regulatory technology space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
